Headquartered in New York, NY Fiscal year ends December NYSE: PFE pfizer.com
Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide. The company operates primarily through its Global Biopharmaceuticals Business (Biopharma) segment, which is organized into the Pfizer U.S. Commercial Division, Pfizer International Commercial Division, and the Global Hospital and Biosimilars Division. Pfizer's portfolio spans primary care (including Eliquis, Prevnar family vaccines, and migraine treatment Nurtec ODT/Vydura), specialty care (anchored by the Vyndaqel family for cardiomyopathy and Xeljanz for immunology), oncology (featuring Ibrance, Padcev, Xtandi, Lorbrena, and biosimilars), and hospital products including sterile injectables and biosimilars. The company also operates Pfizer CentreOne, a contract manufacturing and API sales business. Pfizer maintains a robust R&D pipeline with approximately 20 key pivotal studies planned for 2026, with active programs in oncology, obesity (including a GLP-1 commercialization collaboration in China), immunology (tilrekimig trispecific antibody for atopic dermatitis), vaccines (Lyme disease candidate), and hematology (Hympavzi for hemophilia). The company also participates in the U.S. government's TrumpRx program providing discounted medicines to Americans. Updated
Five stocks cleared 52-week highs this week: Dell topped its prior peak by 6% at $524.14, with Snowflake close behind at 5.7%. Box, Pfizer and Chevron rounded out the list with narrower breakouts.
Pfizer just marked a fresh 52-week high at $29.02, 1.58% above the peak it set on Aug. 25. Anyone anchored to the low-$23 range from a year ago is now looking at a very different reference point.
Seven names printed fresh 52-week highs this week, spanning travel, software and defensives. Box led with a 3.98% clearance over its prior peak, with Coca-Cola, Pfizer, Airbnb and Expedia also at new records.
Six names hit fresh 52-week highs this week: SentinelOne led at 6.14% above its prior peak, with Coca-Cola, Expedia, Airbnb, AbbVie and Pfizer all clearing old ceilings too.
Pfizer closed at $28.24, a new 52-week high that clears the April 1 peak. The drugmaker has now taken out the ceiling that capped it all spring, making that old level the line to defend.
Investors are only learning now, 521 days late, that a Ways and Means Republican's household cleared out four positions on the same March 2025 day, including two healthcare names her committee legislates on. The filing lag is the story: disclosure rules give 45 days, and this one took more than a year past that.
Moderna stock has turned a handful of patient shareholders into believers, but a gain this size forces a choice that most investors never plan for in advance. The pipeline promise is real,…
A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX),…
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company’s messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset…
Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or a ceiling, and the answer hinges on a single pipeline deal that…
Three struggling companies keep sending dividend checks while investors wait for their repairs to kick in, but only one of them has a yield that cash flow actually supports without a fight.
Chris Lange Turning a monthly paycheck into permanent investment income sounds straightforward until you realize how dramatically the required capital swings based on one variable most people overlook when building their retirement portfolio.
Buyers are stepping into Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, evidently. The move comes one session after a Citigroup (NYSE:C) downgrade to Sell, a sign the market still prizes the company’s…
A fat dividend yield can mean a generous payout or a stock the market has already written off, and right now six familiar names are flashing signals that suggest the difference matters…
A 5% Treasury yield raises the bar for every dividend stock in a retirement portfolio, but four large-cap payers in real estate, telecom, tobacco, and healthcare are generating the cash flow to…
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is drawing attention Wednesday after Citigroup downgraded the biotech company to Sell from Hold, arguing that the recent rally has pushed the valuation well ahead…
Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
The 5-year U.S. Treasury yield stands at 5.04%. Arguably, U.S. sovereign debt is the safest investment in the world. A bit of doubt has crept in as U.S. debt topped $40 trillion.…
A fat dividend yield can signal a screaming buy or a slow-motion disaster, and the difference hides in coverage math most investors never check. Six well-known names are flashing the exact warning…
Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most…
Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64…
Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide. The company operates primarily through its Global Biopharmaceuticals Business (Biopharma) segment, which is organized into the Pfizer U.S.
The Wall Street consensus 12-month price target for PFE is $28.91. PFE price prediction →
